"The Foundation Fighting Blindness has launched a Phase II clinical trial
of valproic acid, now underway, to evaluate the drug's effectiveness in
slowing vision loss for people with autosomal dominant forms of
retinitis pigmentosa (adRP), an inherited retinal degeneration that
progressively leads to blindness," according to a post on MedicalNewsToday. Read more.
No comments:
Post a Comment